USAMRICD

What USAMRICD does

USAMRICD (U.S. Army Medical Research Institute of Chemical Defense) is a U.S. Army research institute, subordinate to the U.S. Army Medical Research and Development Command (MRDC), that serves as the nation's designated center of excellence for medical chemical defense. Founded in its current form in 1981 with lineage to chemical weapons defense research dating back to 1917, USAMRICD conducts discovery and development of medical solutions — including prophylactics, pretreatments, antidotes, decontaminants, and diagnostics — against chemical, biochemical, and emerging non-kinetic acute battlefield threats (nerve agents, vesicants, metabolic poisons, pulmonary toxicants, toxic industrial chemicals, toxins of biological origin, and pharmaceutical-based agents). The institute also delivers real-time clinical consultation, high-complexity diagnostic testing, and professional training to military medical personnel, first responders, and federal agencies.

USAMRICD's technology base spans six core research program areas — Toxin Countermeasures, Analytics, Toxicant Countermeasures, Agent Mitigation, Pharmaceutical Sciences, and Nerve Agent Countermeasures — supported by a 526,000-square-foot consolidated facility (opened 2015) at Aberdeen Proving Ground, Maryland, housing specialized capabilities including a 600 MHz NMR spectrometer, field emission scanning electron microscopy, non-invasive multiphoton microscopy, an inhalation toxicology laboratory, and an A2LA-accredited clinical laboratory. The institute's product portfolio includes FDA-approved medical countermeasures (MARK I, CANA, ATNAA, Pyridostigmine Bromide, SERPACWA, RSDL, Midazolam/AAS, naloxone autoinjector), advanced nerve agent treatment systems (INATS-CA, RNATS), the ChemDX ultra-portable field diagnostic, and the TestMate Cholinesterase Kit. Its training portfolio — MCBC, FCBC, HM-CBRNE, and ACPC — is recognized by the U.S. Government Accountability Office as the military gold standard.

USAMRICD does not operate a commercial business model. It is funded entirely through U.S. Department of Defense appropriations and federal grants (DTRA, NIH, CDMRP, CCC-RP), with no commercial revenue, no external shareholders, and no venture or private equity involvement. The institute reaches its users through direct delivery: in-residence, off-site, and distance learning training; A2LA-accredited clinical laboratory testing on human samples submitted CONUS/OCONUS; 24/7/365 clinical consultation to combatant commanders; and technology transfer via the Office of Research and Technology Applications (CRADAs, MTs, MOA/U, IAAs, NDAs) to industry and academia. Customers are exclusively U.S. government entities — DoD, Army Medical Department beneficiaries, deploying military units, and first responders served via DHS — and the workforce of 300+ comprises civilian, military, and contractor personnel.

Name

USAMRICD

Legal name

U.S. Army Medical Research Institute of Chemical Defense

Website

https://usamricd.health.mil

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

51–100 employees

Short description

USAMRICD is the U.S. Army's center of excellence for medical chemical defense, developing FDA-licensed countermeasures, diagnostics, and decontaminants against chemical warfare agents while delivering gold-standard training, clinical consultation, and A2LA-accredited laboratory services to military, federal, and first-responder users, funded entirely through Department of Defense appropriations.

Ownership category

akta.pro rank

Product category

Military Medical Research

NAICS

Medical Laboratories (621511), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Biothreat/Biocontainment & Select Agent Public Health Laboratories (HLAJAIAL)

akta.pro secondary industry

Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Medical chemical defense
• Chemical warfare countermeasures
• Military medical research
• Toxicology research
• Chemical casualty care

Headquarters

HQ city

Aberdeen Proving Ground

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Government Appropriated Funding: USAMRICD is a U.S. Army research institute funded through Department of Defense appropriations, Defense Threat Reduction Agency (DTRA), National Institutes of Health (NIH), Congressionally Directed Medical Research Program (CDMRP), and Combat Casualty Care Research Program (CCC-RP).

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

USAMRICD is the nation's center of excellence for medical chemical defense, developing FDA-approved medical countermeasures (antidotes, pretreatments, diagnostics, and decontamination products) against chemical warfare agents. The institute provides in-residence and off-site training courses in medical management of chemical and biological casualties, operates an A2LA-accredited clinical laboratory for diagnostic testing on human samples, and delivers 24/7 reach-back clinical consultation for warfighters and combatant commanders.

Product overview

USAMRICD is the nation's center of excellence for medical chemical defense, offering a portfolio of medical countermeasures products and training services. The institute developed all currently available medical countermeasures against chemical warfare agents, including MARK I Nerve Agent Antidote Kit, TestMate Cholinesterase Kit, CANA, ATNAA, pyridostigmine, SERPACWA, RSDL, Midazolam (AAS), Nats nerve agent treatment systems, ChemDX diagnostics, and naloxone autoinjector. Training services include FCBC, HM-CBRNE, MCBC, and ACPC courses, all recognized as gold standard for military and civilian medical professionals. The institute also operates an A2LA accredited clinical laboratory providing diagnostic testing for chemical agent exposure confirmation.

Differentiator

Problem solved

Functional benefit

Products and services

• MARK I Nerve Agent Antidote Kit FDA-approved nerve agent antidote kit providing medical protection against chemical warfare nerve agents for military personnel.
• TestMate Cholinesterase Kit Diagnostic kit that measures blood enzymes erythrocyte AChE and/or plasma cholinesterase, providing detection of nerve agent exposure in less than 4 minutes.
• CANA (Convulsant Antidote Nerve Agent) Diazepam autoinjector for field treatment of nerve agent-induced seizures and convulsions in military personnel.
• ATNAA (Antidote Treatment Nerve Agent Autoinjector) FDA-approved combination autoinjector for nerve agent antidotes for military use.
• Pyridostigmine Bromide Pretreatment medication FDA-approved under the Animal Efficacy Rule to increase survival after soman nerve agent exposure.
• SERPACWA (Skin Exposure Reduction Paste Against Chemical Warfare Agents) Topical skin protectant paste that reduces skin absorption of chemical warfare agents.
• RSDL (Reactive Skin Decontamination Lotion) Skin decontamination lotion for removal of chemical warfare agents from skin.
• Midazolam (Advanced Anticonvulsant System)

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered core and major.

• U.S. Army Medical Research Institute of Infectious Diseases (MRIID)coreStrategic or Co-development PartnerMRICD works closely with USAMRIID to conduct the Medical Management of Chemical and Biological Casualties Course (MCBC), Field Management of Chemical and Biological Casualties Course (FCBC), and Hospital Management of CBRNE Incidents Course (HM-CBRNE). Both institutes collaborate on off-site training programs and share expertise in medical countermeasures.
• Oak Ridge Institute for Science and Education (ORISE)coreStrategic or Co-development PartnerORISE operates a research participation program for the U.S. Department of Energy with a memorandum of agreement established for DoD participation. MRICD hosts undergraduate, graduate, and postgraduate research participants through this program to broaden the nation's base of scientists and engineers.
• Industry Partners and Academic InstitutionscoreStrategic or Co-development PartnerMRICD collaborates with private sector and academia nationally and internationally. The Office of Research and Technology Applications (ORTA) facilitates technology transfer mechanisms including Cooperative Research and Development Agreements (CRADA), Material Transfers (MT), Memorandums of Agreement/Understanding (MOA/U), Interagency Agreements (IAA), and Non-Disclosure Agreements (NDAs).
• U.S. Army Medical Research and Development Command (MRDC)coreStrategic or Co-development PartnerMRICD is subordinate to USAMRDC and manages a diversified portfolio of medical chemical and biochemical threat agent research projects for the Department of Defense and other federal agencies.
• U.S. Army Medical Center of Excellence (MEDCoE)coreStrategic or Co-development PartnerProfessional development courses are sponsored by MEDCoE and the Office of the Surgeon General. Upon successful completion, courses are placed in records of active duty medical personnel.
• Department of Homeland Security (DHS)majorStrategic or Co-development PartnerMCBC and FCBC courses are listed in the DHS Office of Grants and Training Federal Sponsored Course Catalog as well as the DHS Compendium of Federal Terrorism Training for State and Local Audiences.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Regional players

• Institut de Recherche Biomédicale des Armées (IRBA): IRBA is the French Armed Forces Biomedical Research Institute — the French counterpart to USAMRICD with a similar medical CBRN defense mission. It is a regional peer operating in allied European CBRN defense research with comparable countermeasure R&D and training scope.

Broad incumbents

• Science Applications International Corporation (SAIC): SAIC operates significant DoD CBRN and chemical defense life science support contracts, including technical and operational support to USAMRICD's mission areas. It is a broad incumbent peer providing scientific, engineering, and technical services to chemical defense programs at national scale.
• MRIGlobal: MRIGlobal is a major non-profit contract research organization with deep DoD CBRN and infectious disease work, operating analytical, diagnostic, and countermeasure development labs. It is a broad incumbent peer competing for CBRN medical R&D contracts at comparable workforce scale.
• Battelle Memorial Institute: Battelle operates major CBRN defense, analytical chemistry, and life science contract research labs that contract with DoD on chemical defense R&D. It is a broad incumbent that competes with USAMRICD for CBRN government contracts and operates comparable inhalation toxicology and analytical chemistry facilities.

Direct peers

• Naval Medical Research Center (NMRC): NMRC is the Navy's counterpart to USAMRICD in military medical research, with comparable DoD medical countermeasure development, clinical lab operations, and military medical training. Both operate under service-specific research commands with similar FDA-track translational pipelines.
• U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID): USAMRIID is USAMRICD's sister institute under MRDC, focused on biological warfare defense. It is the closest direct peer — both are DoD medical research institutes, both operate A2LA-style labs, both deliver gold-standard training (MCBC, FCBC are jointly run), and both conduct FDA-track countermeasure R&D for weapons of mass destruction.
• Walter Reed Army Institute of Research (WRAIR): WRAIR is the U.S. Army's flagship medical research institute covering infectious disease, brain health, and military medicine. It is a direct peer in the DoD medical R&D ecosystem, sharing MRDC oversight, FDA-track countermeasure development, and military medical training missions.
• UK Defence Science and Technology Laboratory (Dstl): Dstl is the United Kingdom's lead government laboratory for chemical and biological defense science. It is the closest international peer — comparable mission scope (CWA medical countermeasures, field diagnostics, CBRN training), comparable regulatory track record, and comparable interagency partnerships.
• Defense Threat Reduction Agency (DTRA): DTRA is a primary funder and coordinating agency for U.S. chemical and biological defense R&D, including direct grants to USAMRICD. It is a peer in the CBRN countermeasure mission space and operates related threat assessment and agent science programs.
• Air Force Research Laboratory (711th Human Performance Wing): The 711th HPW is the Air Force's lead medical and human performance research wing under AFRL. It is a direct DoD medical R&D peer with comparable workforce scale, military medical countermeasure development, and clinical research capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/usamricd

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about USAMRICD